akoyabio.com (AKYA) - יחס יתרת חוב לטווח ארוך להון

Akoya Biosciences is expanding the implementation of PhenoCycler digital systems for the detailed study of cellular structures, aiming to secure a leading position in the B2B diagnostics segment. This price action chart (separate_debt_long_eq) reflects the current value of 0.00. Business resilience is driven by unique patents for biochemical components and strict instrument integration standards, which limit third-party manufacturers' access to the installed equipment base.

Akoya Biosciences (AKYA) is advancing its leadership in spatial biology through the high-precision PhenoCycler platform. Investing in such complex technologies requires an assessment of long-term financial sustainability. This metric compares liabilities with a maturity of over one year against equity. Low leverage minimizes risks amid interest rate volatility. By analyzing the long-term debt-to-equity ratio, an investor determines the business's margin of safety.